MAIA Biotechnology, Inc. (MAIA) has released an update.
MAIA Biotechnology, Inc. announced new interim data from the THIO-101 Phase 2 clinical trial, which is studying THIO in combination with Libtayo® for non-small cell lung cancer. The trial has dosed 60 patients and found a 100% disease control rate in second-line and 88% in third-line treatments. The data met statistical requirements to advance to the next trial phase. In 2024, the company aims to develop second-generation telomere-targeting prodrugs derived from lipid-modified THIO molecules, expected to be more potent at lower doses.
For further insights into MAIA stock, check out TipRanks’ Stock Analysis page.
